This disclosure provides multifunctional conjugate molecules in which at least one therapeutic agent is covalently attached to a cannabinoid. The disclosed conjugate molecules are designed to deliver therapeutic benefits of both components, with release of the cannabinoid upon binding of the therapeutic agent component to its target conveying further therapeutic benefits, and can be used to treat cancer, glaucoma, confusion or dementia, and other disorders.

A disulfiram derivative of formula (I)

##STR00001##

wherein R.sub.1 and R.sub.2 are independently —CH.sub.2CH.sub.2COOH, —CH.sub.2CH.sub.2COOEt, optionally substituted methylenepyridyl, optionally substituted methylenefuranyl, or optionally substituted methylenethiopenyl, may be useful in aldehyde dehydrogenase 1a1 (ALDH1a1) and/or monoacylglycerol lipase (MAGL)-mediated diseases or disorders. Such derivatives may avoid or limit aldehyde dehydrogenase 2 (ALDH2) and/or fatty acid amide hydrolase (FAAH) antagonism.

A disulfiram derivative of formula (I)

##STR00001##

wherein R.sub.1 and R.sub.2 are independently —CH.sub.2CH.sub.2COOH, —CH.sub.2CH.sub.2COOEt, optionally substituted methylenepyridyl, optionally substituted methylenefuranyl, or optionally substituted methylenethiopenyl, may be useful in aldehyde dehydrogenase 1a1 (ALDH1a1) and/or monoacylglycerol lipase (MAGL)-mediated diseases or disorders. Such derivatives may avoid or limit aldehyde dehydrogenase 2 (ALDH2) and/or fatty acid amide hydrolase (FAAH) antagonism.

A disulfiram derivative of formula (I) ##STR00001##
wherein R.sub.1 and R.sub.2 are each independently an optionally substituted alkyl, an optionally substituted cycloalkyl, an optionally substituted arylalkyl, or an optionally substituted heteroarylalkyl, and with the proviso that R.sub.1 and R.sub.2 are not both ethyl, both benzyl, both —CH.sub.2CH.sub.2OH, or both ##STR00002##
A pharmaceutical composition containing the disulfiram derivative of formula (I), and a method of treating ALDH1a1- and/or MAGL-mediated diseases or disorders.

A disulfiram derivative of formula (I) ##STR00001##
wherein R.sub.1 and R.sub.2 are each independently an optionally substituted alkyl, an optionally substituted cycloalkyl, an optionally substituted arylalkyl, or an optionally substituted heteroarylalkyl, and with the proviso that R.sub.1 and R.sub.2 are not both ethyl, both benzyl, both —CH.sub.2CH.sub.2OH, or both ##STR00002##
A pharmaceutical composition containing the disulfiram derivative of formula (I), and a method of treating ALDH1a1- and/or MAGL-mediated diseases or disorders.

A disulfiram derivative of formula (I)

##STR00001##

wherein R.sub.1 and R.sub.2 are each independently an optionally substituted alkyl, an optionally substituted cycloalkyl, an optionally substituted arylalkyl, or an optionally substituted heteroarylalkyl, and with the proviso that R.sub.1 and R.sub.2 are not both ethyl, both benzyl, both —CH.sub.2CH.sub.2OH, or both

##STR00002##

A pharmaceutical composition containing the disulfiram derivative of formula (I), and a method of treating ALDH1a1- and/or MAGL-mediated diseases or disorders.

A disulfiram derivative of formula (I)

##STR00001##

wherein R.sub.1 and R.sub.2 are each independently an optionally substituted alkyl, an optionally substituted cycloalkyl, an optionally substituted arylalkyl, or an optionally substituted heteroarylalkyl, and with the proviso that R.sub.1 and R.sub.2 are not both ethyl, both benzyl, both —CH.sub.2CH.sub.2OH, or both

##STR00002##

A pharmaceutical composition containing the disulfiram derivative of formula (I), and a method of treating ALDH1a1- and/or MAGL-mediated diseases or disorders.

A disulfiram derivative of formula (I) ##STR00001##
wherein R.sub.1 and R.sub.2 are independently CH.sub.2CH.sub.2COOH, CH.sub.2CH.sub.2COOEt, optionally substituted methylenepyridyl, optionally substituted methylenefuranyl, or optionally substituted methylenethiopenyl, may be useful in aldehyde dehydrogenase 1a1 (ALDH1a1) and/or monoacylglycerol lipase (MAGL)-mediated diseases or disorders. Such derivatives may avoid or limit aldehyde dehydrogenase 2 (ALDH2) and/or fatty acid amide hydrolase (FAAH) antagonism.

A disulfiram derivative of formula (I) ##STR00001##
wherein R.sub.1 and R.sub.2 are independently CH.sub.2CH.sub.2COOH, CH.sub.2CH.sub.2COOEt, optionally substituted methylenepyridyl, optionally substituted methylenefuranyl, or optionally substituted methylenethiopenyl, may be useful in aldehyde dehydrogenase 1a1 (ALDH1a1) and/or monoacylglycerol lipase (MAGL)-mediated diseases or disorders. Such derivatives may avoid or limit aldehyde dehydrogenase 2 (ALDH2) and/or fatty acid amide hydrolase (FAAH) antagonism.

A dithiocarbamate functionalized dendrimer with an alkylenediamine core, a dithiocarbamate pendant functional group and a dithiocarbamate end functional group, as a soil heavy metal immobilization amendment, and a preparation method thereof are provided. The dithiocarbamate functionalized dendrimer has a chemical formula of (CH.sub.2).sub.a{N[CH.sub.2CH.sub.2COOCH.sub.2C(C.sub.2H.sub.5)(CH.sub.2OCOCH.sub.2CH.sub.2N(CSSM)CH.sub.2(CH.sub.2).sub.bCH.sub.2N(CSS M).sub.2).sub.2].sub.2}.sub.2, wherein a is a positive integer larger than 2; b is a positive integer at a range of 0-4; and M is Na.sup.+, NH.sub.4.sup.+ or K.sup.+. The dithiocarbamate functionalized dendrimer with the alkylenediamine core is used for an in-suit immobilization remediation for soil contaminated by heavy metals, and has advantages of a small dosage, high efficiency, safety and rapidness. The dendrimer is able to effectively immobilize exchangeable and carbonated bound forms of the heavy metals, in such a manner that the immobilized heavy metals are able to resist an influence from natural environment for a long term, such as an acid rain.